JRENHEP005 11..19 jrenhep.com REVIEW ARTICLE Anaemia of Chronic Kidney Disease: What We Know Now Anoushka R. Krishnan 1, Debbie Trinder 2,3,4, Anita C. G. Chua 2,3,4, Aron Chakera 1, Grant A. Ramm 5,6, John K. Olynyk 2,3,7,8,9,10 1Department of Nephrology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia; 2School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia; 3Fiona Stanley Hospital, Murdoch, Western Australia, Australia; 4Harry Perkins Institute of Medical Research, Murdoch, Western Australia, Australia; 5QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; 6Faculty of Medicine and Biomedical Sciences, The University of Queensland, Brisbane, Queensland, Australia; 7Department of Gastroenterology, Fiona Stanley Hospital, Perth, Western Australia, Australia; 8Faculty of Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia; 9School of Biomedical Sciences, Curtin University, Bentley, Western Australia, Australia; 10School of Veterinary and Life Sciences, Murdoch University, Murdoch, Western Australia, Australia Abstract Our understanding of the pathophysiology of the anaemia of chronic kidney disease (CKD) has improved considerably in the last decade with the discovery of the iron regulatory peptide hepcidin. Reduced clearance of hepcidin and the presence of a chronic inflammatory state contribute to elevated hepcidin levels in kidney disease. The recent discovery of the various factors and signalling pathways regulating hepcidin has opened up an exciting avenue for research into the development of newer agents that could treat anaemia of CKD. This review highlights our current understanding of iron metabolism in health, the regulators of hepcidin, issues associated with the current available therapies for the treatment of anaemia in CKD and potential novel therapies that could be available in the near future targeting the various factors that regulate hepcidin. Keywords: anaemia; chronic kidney disease; iron metabolism; hepcidin; inflammation; erythropoietin-stimulating agents Received: 28 November 2016; Accepted after revision: 02 January 2017; Published: 03 February 2017. Author for correspondence: John K. Olynyk, Fiona Stanley Hospital, 11, Robin Warren Drive, Murdoch, Western Australia, Australia 6150, Postal address: Locked Bag 100, PALMYRA DC, WA 6961. Email: john.olynyk@health.wa.gov.au How to cite: Krishnan AR et al. Anaemia of chronic kidney disease: what we know now. J Ren Hepat Disord 2017;1(1):11–19. DOI: http://dx.doi.org/10.15586/jrenhep.2017.5 Copyright: Krishnan AR et al. License: This open access article is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). http://creativecommons.org/licenses/by/4.0 Introduction Anaemia of chronic kidney disease (CKD) is widely prevalent in patients with renal impairment and is associated with signifi- cant morbidity and mortality (1, 2). Deficient erythropoietin (EPO) production and reduced bioavailability of iron ulti- mately lead to absolute or functional iron deficiency anaemia. Hepcidin, an iron regulatory protein produced in the liver by hepatocytes, plays an important role in iron metabolism by regulating iron absorption from the duodenum and iron release from macrophages by interacting with, and inactivating, ferroportin—the iron transport protein (3). Hep- cidin is regulated by a number of factors including iron status, inflammation, erythropoiesis and hypoxia, which are often affected by kidney disease. Iron Metabolism Iron is an essential trace element required for a number of catabolic and metabolic processes within the body. As there are no effective means of excreting iron, the regulation of dietary iron absorption from the duodenum plays an Codon Publications Journal of Renal and Hepatic Disorders 2017; 1(1): 11–19 http://dx.doi.org/10.15586/jrenhep.2017.5 http://creativecommons.org/licenses/by/4.0 important role in iron homeostasis. In healthy individuals, approximately 1–2 mg of iron is absorbed from the diet per day to maintain iron balance. Once absorbed, the iron is bound by the plasma protein transferrin and is transported to the tissues where most of the iron is taken up by the bone marrow for incorporation into haemoglobin for ery- thropoiesis and to a lesser degree by the muscle for the synthesis of myoglobin and respiratory enzymes. Excess iron is stored primarily in the liver. Macrophages degrade erythrocyte- derived haemoglobin and release the iron back into the plasma so that it can be re-utilised for erythropoiesis in the bone marrow. If the availability of iron for erythropoiesis is insufficient, anaemia will develop. Too much iron can result in iron overload. Common causes include genetic diseases such as hereditary haemochromatosis and acquired causes such as from transfusional overload and repeated parenteral iron infusions. Iron excess is detrimental to health as this gen- erates free radicals causing oxidative stress and tissue damage primarily in the liver, heart and pancreas (4–8). Hepcidin and Its Regulators Iron metabolism is tightly regulated by the hormone hepcidin which is highly expressed by hepatocytes and at lower levels in other tissues including the kidneys (9). Hepcidin, a 25- amino acid cysteine-rich peptide, is a negative regulator of iron absorption by the intestine and iron release from macro- phages and hepatic stores. It is secreted into the circulation and binds to the iron exporter ferroportin, expressed on the surface of enterocytes, macrophages and hepatocytes, causing ferroportin internalisation and degradation. This limits the absorption and release of iron and increases retention in the liver and macrophages (6, 10). In addition to regulating iron metabolism, hepcidin may also contribute indirectly to host defence mechanisms by redu- cing body iron concentrations, as iron is needed for bacterial growth and low levels of iron are thought to be bacteriostatic. In murine models and cultured macrophages, hepcidin has been found to modulate lipopolysaccharide-induced tran- scription, suggesting it might have a role in modulating acute inflammatory responses to bacterial infections (11, 12). The two main positive regulators of hepcidin are iron sta- tus and inflammation with higher levels limiting the availability of iron for erythropoiesis and other iron-dependent processes. Similarly, erythropoiesis and hypoxia downregulate hepci- din expression, resulting in increased bioavailability of iron (Figure 1). These factors regulate hepcidin levels via pathways listed in Table 1, and some of these pathways could be poten- tial targets for novel therapies to treat anaemia of CKD. Regulation of Hepcidin Iron status Tissue iron stores and circulating transferrin-bound iron exert distinct signals that regulate hepcidin expression in hepatocytes. Hepcidin gene transcription is stimulated by the dual effect of liver iron stores and the concentration of plasma holotransferrin (iron-saturated transferrin), conveyed through iron-regulated production of bone morphogenetic proteins (BMP) acting on BMP receptors and the associated mothers against decapentaplegic-related protein (SMAD) pathway (13). Intra- cellular iron stores interact with hepcidin via the BMP6 path- way activating SMAD and increasing hepcidin levels. Circulating transferrin-bound iron exerts its effects via the hae- mochromatosis protein (HFE)/transferrin receptor 2 (TFR2) pathway (14, 15). Mutations of these receptors are associated with hereditary haemochromatosis resulting in iron overload via dysregulated hepcidin expression (16, 17). Inflammation Hepcidin levels are increased by states of inflammation, and this is thought to have evolved as a host defence mechanism. Interleukin-6, acting through the JAK2/STAT3 pathway and, to a lesser extent, interferon γ, and interleukin-1 are the primary inflammatory inducers of hepcidin expression (18, 19). Recently, a new inflammatory signalling pathway was identified, stimulating hepcidin production via activin B, BMP receptors and SMAD (20). Hypoxia This is a potent inhibitor of hepcidin production, even in the absence of anaemia, and thus increases iron availability (18). Hypoxia-inducible factors (HIFs) are transcription factors that regulate expression of genes in response to hypoxia including genes required for iron metabolism and erythropoi- esis. EPO synthesis is regulated in the liver and kidney via HIF-2α. HIF activity is controlled by prolyl-4-hydroxylase domains (PHD), which act as oxygen sensors. At normal oxy- gen concentrations, PHD enzymes hydroxylate the HIF-α subunit resulting in its rapid degradation. At lower concen- trations of oxygen, HIF–PH activity is reduced, and there is accumulation of HIF-α, leading to increased levels of EPO and its receptor, and decreased hepcidin levels, ultimately increasing iron availability and erythropoiesis (21–24). Simi- lar effects were seen during hypoxia at high altitude. In a study of healthy volunteers who were exposed to high altitude levels (3400–5400 m above sea level), hypoxia induced a marked suppression of hepcidin, which appeared to result from the combined action of hypoxia-induced increased ery- thropoiesis and iron depletion (25). Erythropoiesis Increased erythropoiesis appears to suppress hepcidin levels, allowing for higher iron bioavailability to meet increased demands for red blood cell production in such states. Erythro- ferrone (ERFE), a relatively new hormone identified in 2014, was found to regulate iron metabolism by decreasing hepcidin levels during periods of stress erythropoiesis (26). This protein Krishnan AR et al. Codon Publications Journal of Renal and Hepatic Disorders 2017; 1(1): 11–19 12 is thought to be the long-sought erythroid factor that inhibits hepcidin during increased erythropoietic activity and may contribute to the pathogenesis of iron-loading anaemias. Kautz et al. showed in animal models that bleeding or admin- istration of EPO leads to release of ERFE from erythroblasts, which acts directly on hepatocytes to suppress hepcidin (26). In ineffective erythropoiesis, ERFE secreted by the massively increased numbers of erythroid precursors may overwhelm the iron storage signal and shut off hepcidin production (26, 27). Erythropoietin-stimulating agents (ESAs) are widely used to treat anaemia of CKD. ESAs significantly suppress levels of serum hepcidin and ferritin, resulting in effective erythropoiesis LIVER IRON IRON IRON IRON IRON INTESTINE IRON MACROPHAGE Erythropoiesis Hypoxia ERFE ERFE EPO KIDNEY BONE MARROW NORMAL IRON HOMEOSTASIS Positive Regulations Inflammation Iron Negative regulators Erythropoiesis Hypoxia CHRONIC KIDNEY DISEASE Positive regulators Inflammation Iron therapy Erythropoietin deficiency Negative regulators Iron deficiency Anaemia Hypoxia Erythropoietin therapy Iron Inflammation HEPCIDIN HEPCIDIN Ferroportin Ferroportin Ferroportin Figure 1. Schematic representation of the role of hepcidin in iron metabolism in health and in chronic kidney disease (CKD). Both iron and erythropoietin (EPO) are required for the production of red blood cells in the bone marrow. Hepcidin regulates iron absorp- tion from the intestine, macrophage iron recycling from senescent red blood cells and iron release from the liver via ferroportin, the iron transport protein. Hepcidin causes degradation of ferroportin leading to cellular iron retention and decreased absorption of ingested iron. Several factors including iron and inflammation act directly on the liver to up-regulate hepcidin production. Erythro- poiesis and hypoxia negatively regulate hepcidin production indirectly, by increasing EPO production by the kidneys. This stimulates synthesis of erythroferrone (ERFE) by the bone marrow, which in turn controls liver hepcidin production. In CKD, anaemia occurs due to reduced EPO production from the kidneys and from reduced iron absorption and availability, the latter resulting from elevated levels of hepcidin. In CKD, hepcidin levels are raised due to the combination of increased inflammation, decreased EPO levels and reduced renal clearance. EPO therapy decreases hepcidin levels leading to iron mobilisation from body stores during erythropoiesis. Table 1. Regulation of hepcidin Regulators Signalling pathway Iron status BMP6/SMAD and HFE/TFR2 Inflammation (interleukin-6) JAK2/STAT3, activin B Hypoxia HIFs and EPO Erythropoiesis EPO and ERFE BMP6: bone morphogenic protein 6; SMAD: mothers against decapentaplegic-related protein; HFE/TFR2: haemochromatosis iron protein/ transferrin receptor 2; JAK: Janus kinase; STAT3: signal transducer and activation of transcription 3; HIFs: hypoxia-inducible factors; EPO: erythropoietin; ERFE: erythroferrone. Anaemia of chronic kidney disease Codon Publications Journal of Renal and Hepatic Disorders 2017; 1(1): 11–19 13 and release of stored iron (28, 29). Honda et al. examined the association between ERFE and biomarkers of iron metabolism in haemodialysis patients and found that levels of ERFE were inversely correlatedwith levelsof hepcidin and ferritin and posi- tively correlated with soluble transferrin receptor. They also showed that the use of ESAs increased the levels of ERFE that regulated hepcidin and led to iron mobilisation from body stores during erythropoiesis (30). Additional studies of this pathway and its potential effects in CKD are warranted. Anaemia of CKD Anaemia is a common feature of CKD, which increases in prevalence as the severity of CKD progresses. Anaemia in patients with renal failure is associated with poor quality of life and high morbidity rates as evidenced by increased hospi- talisations and incidence of cardiovascular disease incorpor- ating left ventricular hypertrophy, heart failure and higher rates of mortality from adverse cardiac events (31, 32). Anaemia of CKD is typically normochromic and normo- cytic and is thought to result from two main mechanisms— deficient production of EPO by the kidney and reduced iron absorption and availability. In CKD, iron deficiency can be classified into absolute iron deficiency (marked by low iron stores and circulating iron concentrations) and functional iron deficiency (marked by low circulating iron in the setting of normal iron stores), with both forms leading to iron- restricted erythropoiesis that leads to anaemia of CKD as well as ESA hyporesponsiveness (33). The reduced absorption and bioavailability of iron is thought to result from excessive production of hepcidin (34, 35), partly contributed by reduced renal clearance (36–38) and partly in response to elevated interleukin-6 or other pro- inflammatory cytokines produced in CKD (6, 39, 40). CKD is associated with a chronic inflammatory state, in particular, elevated interleukin-6 plasma levels, which are a major media- tor of the acute-phase response. In In CKD patients, higher levels of interleukin-6 may be related to loss of kidney function, uraemia and its sequelae (such as fluid overload and susceptibil- ity to infections) and possibly dialysis related factors. (41). Excess levels of hepcidin contribute to impaired dietary iron absorption and iron release from body stores (37, 42, 43). Reduced iron availability occurs due to retention of iron in macrophages and hepatocytes, thus elevating iron stores but reducing serum iron and transferrin saturation levels (func- tional iron deficiency), causing anaemia even in the presence of adequate iron reserves, in contrast to true iron deficiency. Additional mechanisms have been suggested to contribute to the pathogenesis of anaemia of CKD, including shortened red blood cell lifespan, nutritional deficiencies (folate and B12) due to anorexia, loss via dialysis and increased iron losses (due to uraemia-related platelet dysfunction causing subclinical blood loss, frequent phlebotomy and trapping of blood in dialysis circuits) (44, 45). More recently, there has been an interest in vitamin D and its associations with anaemia. Initially, this was attributed to the anti-inflammatory and pro-erythropoietic effects of vita- min D (46). Data now suggest that vitamin D may actually modulate iron homeostasis via hepcidin, with a study show- ing that 1,25-dihydroxycholecalciferol directly inhibits hepci- din expression by binding to a vitamin D response element in the gene coding for hepcidin (47). Current Management of Anaemia of CKD Intravenous iron therapy and ESAs are the cornerstones of current therapy for anaemia related to CKD; however, they are not without their side effects. Issues with iron therapy With regard to iron administration during episodes of acute infection or inflammation which results in elevated serum ferritin levels, opinions suggest that iron therapy should be withheld under such circumstances, citing a concern that iron may further help in the proliferation of microorganisms. Iron loading has been shown to be associated with worse outcomes in infectious diseases such as malaria, tuberculosis and HIV (48–50). However, surprisingly, the recent intravenous iron or placebo for anaemia in the intensive care unit (IRONMAN) clinical trial demonstrated no adverse effects of ironadministra- tion in acutely unwell intensive care patients but there were sig- nificant improvements in haemoglobin levels (51). Moreover, there are concerns related to iron therapy- induced iron overload, with a study by Barany et al. suggesting that haemodialysis patients with very high ferritin levels have a mean liver iron concentration similar to that of patients with untreated idiopathic haemochromatosis (52). Iron de- position has been associated with the pathogenesis of several other disorders such as diabetes mellitus, neurodegenerative diseases and atherosclerosis (53–55). Iron could be a potential link between oxidative stress and cardiovascular disease (56, 57). Iron has been found in advanced human atherosclerotic plaques (58), and free iron may play a role in plaque destabilisation post intra-plaque haemorrhage (59), although, despite pathogenic hypotheses, hard evidence linking iron, oxidative stress and cardiovas- cular disease is limited (60). Also, the long-term effects of high-dose iron therapy remain unclear. Large prospective randomised controlled trials in the CKD population are long overdue to assess the efficacy of recurrent iron infusions with regard to long-term safety, mortality and morbidity. In the absence of clear target values for serum ferri- tin and transferrin, clinicians continue to make a case-by-case decision on the best treatment option for their patients. Advent of ESAs The treatment of anaemia of CKD was revolutionised in the 1980s with the development of recombinant ESAs, which has reduced the need for blood transfusions (which in turn Krishnan AR et al. Codon Publications Journal of Renal and Hepatic Disorders 2017; 1(1): 11–19 14 reduces the chances of acquiring blood-borne infection and avoids sensitisation in potential renal transplant candidates) (61, 62) and improves exercise tolerance, quality of life symp- toms and left ventricular hypertrophy (63, 64). Risk profile of ESAs The target haemoglobin level in the treatment of CKD has been debated for some time, and a number of clinical trials have sought to assess whether full correction of anaemia to normal levels confers benefits; however, results have been dis- appointing. In 2006, two large randomised control trials in CKD showed that complete correction of anaemia had no effect (65) or conferred a greater risk for attaining the primary composite cardiovascular endpoint (66). The Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT)-diabetic patients showed no survival benefit in patients when a haemoglobin target of 13 g/l was set and a secondary analysis suggested higher risk for stroke, death resulting from cancer in patients with a history of malignan- cies, and venous and arterial thromboembolic events (67, 68). Another limitation of ESAs is that they also necessitate regular injections, either subcutaneous for patients with CKD and on peritoneal dialysis or via the intravenous route for patients on haemodialysis. Supra-physiologic effects of ESAs, especially at high doses, have off-target effects on other cell types expressing EPO receptors including endothe- lial cells. This results in adverse effects such as hypertension (69), intimal hyperplasia especially in the setting of inflamma- tion (70) and promotion of tumour growth (71). Other draw- backs include the development of ESA hyporesponsiveness (which can occur in 10%–20% of patients with end-stage kid- ney disease). Patients needing greater doses are those with concomitant infectious, inflammatory or malignant condi- tions resulting in relative ESA resistance, which may contri- bute to increased mortality (72). Given the high costs and potential disadvantages of ESAs, further elucidation of the molecular mechanisms of anaemia in CKD and the development of better targeted therapies have become a priority. The Hunt for New Therapies Pentoxifylline Given that inflammation contributes to elevated hepcidin levels and may contribute to ESA hyporesponsiveness, it was thought that pentoxifylline might partially correct pro- inflammatory cytokines levels in CKD, resulting in improved iron utilisation and erythropoiesis. The drug has been shown to have anti-inflammatory properties (anti-apoptosis, anti- oxidant, anti-TNF-α and anti-IFN-γ) (73–75). In the hand- ling erythopoietin resistance with oxpentifylline (HERO) trial, which was a double-blind, randomised, placebo-controlled trial, Johnson et al. studied the effects of pentoxifylline on ESA hyporesponsive anaemia in 53 patients with CKD stage 4 or 5 (including dialysis) (76). Although pentoxifylline did not significantly modify ESA hyporesponsiveness as measured by the erythropoiesis resistance index, it did safely increase mean haemoglobin concentration significantly, rela- tive to the control group. A smaller sub-study of the HERO trial examined the effect of pentoxifylline on serum hepcidin level but found no significant difference in patients who received the drug as compared to those on placebo (77). A small uncontrolled pilot study that looked at the effect of this drug on inflammation showed that pentoxifylline reduced levels of interleukin-6 and improved haemoglobin levels in non-inflammatory moderate to severe CKD (78). A systematic review and meta-analysis of 11 studies did not demonstrate conclusive effects of pentoxifylline on haematocrit and ESA dosing (79). Whether this drug may provide any benefits remains to be seen in larger randomised trials. HIF–PH inhibitors The role of hypoxia in hepcidin regulation has been briefly explained above. Small-molecule inhibitors of the PHD enzymes mimic the response to a cellular reduction in oxygen levels, increase HIF levels and thereby increase EPO produc- tion, thus promoting erythropoiesis. These drugs are in vari- ous phases of clinical development for the treatment of renal anaemia. One such agent roxadustat, an oral HIF–PH inhibitor, was trialled in 60 incident dialysis patients in a phase 2 clinical trial and was shown to increase haemoglobin levels by ≥2.0 g/l within 7 weeks, regardless of baseline iron repletion status, C-reactive protein levels, iron regimen or dialysis modality. It was also found to reduce serum hepcidin levels. Roxadustat by inhibiting HIF–PHs results in increased levels of HIF and stimulates erythropoiesis (80). More recently, Pergola et al. studied the effect of vadadustat as compared to placebo in 210 non-dialysis-dependent CKD patients (stages 3–5) in a 20-week multi-centre phase 2b study (81). They showed that 55% of the candidates who received vadadustat achieved the primary end point (percen- tage of participants who during the last 2 weeks of the treat- ment achieved or maintained a mean haemoglobin level of >11 g/dl or an increase in haemoglobin level of ≥1.2 g/dl over the pre-dose average) as compared to 10% of the placebo- treated candidates, and the drug raised and maintained haemo- globin in a predictable manner with no significant side effects as compared to placebo. They noted significant increases in both reticulocyte and total iron-binding capacity and signifi- cant decreases in both serum hepcidin and ferritin levels. Similar small preclinical and clinical studies have demon- strated some pleiotropic effects of this class of drug (molidu- stat corrected anaemia in rat studies and also helped normalise blood pressure; daprodustat was shown to improve cholesterol levels) (82, 83). Advantages of this new class of drug include oral administration, low immunogenicity, Anaemia of chronic kidney disease Codon Publications Journal of Renal and Hepatic Disorders 2017; 1(1): 11–19 15 product stability and possibly lower costs as well as potential cardiovascular benefits (84). Safety concerns of targeting the HIF pathway include the potential for raised Vascular endothelial growth factor (VEGF) production, which is a HIF-related angiogenic growth factor known to be associated with vasculopathies and progression of tumour growth (85), and the potential for development of pulmonary and systemic hypertension, given the role of HIF in regulation of vascular tone (86, 87). Results of phase 3 trials that continue to monitor for these side effects are awaited. Hepcidin antagonists Several agents that can antagonise hepcidin are under devel- opment, including neutralising hepcidin peptide by anti- hepcidin antibodies or by engineered hepcidin binders such as anticalins (engineered human proteins that can bind specific target molecules). Cooke et al. demonstrated an increase in haemoglobin by 1.5 g/dl within 1 week of injection of an anti-hepcidin antibody in humanised murine models where endogenous mouse hepcidin was replaced by human hepcidin and inflammation was induced using heat-killed Brucella abortus (88). The most effective method was the combination of ESA and anti-hepcidin antibody, which increased haemo- globin by >3 g/dl after 1 week compared with inflamed mice injected with a control antibody. The improvement in haemo- globin resulted from increased serum iron levels and better haemoglobinisation of erythroid precursors, without affecting inflammatory responses in these mice. Pieris pharmaceuticals are conducting a phase 1b placebo-controlled study using a hepcidin-antagonist in patients on dialysis, after demonstrat- ing that the drug was shown to reduce hepcidin levels and increase serum iron and transferrin saturation in 48 healthy male subjects in a single ascending dose study with no signifi- cant adverse effects (89). Vitamin D Recent studies have shown that vitamin D concentrations are inversely associated with hepcidin levels and positively asso- ciated with haemoglobin and iron concentrations (36, 90, 91). Zughaier et al. demonstrated in vitro that vitamin D is asso- ciated with reduced production of pro-hepcidin cytokines such as IL-6 and interleukin-1β. In their in vivo pilot study of 38 patients with early stage (2/3) CKD who received high doses of oral vitamin D3 as compared to placebo, the percent change from baseline to 3 months in serum 25-hydroxy chole- calciferol concentrations was inversely associated with the per- cent change in serum hepcidin levels (92). These findings are relevant as a large majority of patients with CKD are vitamin D deficient, and correction of vitamin D levels, as an adjunct therapy, is attractive, given the inexpensive cost, easy avail- ability, favourable safety profile and potential to reduce dependence on other more expensive therapies. Future Considerations Although there is uncertainty surrounding optimal laboratory investigations and haemoglobin targets, our understanding of the mechanisms causing anaemia in CKD has improved over the years. New markers of anaemia are being investigated, and a number of new agents are in evaluation, awaiting com- pletion of phase 2/3 clinical trials. These novel treatments may not only be safer and cheaper but could also reduce our dependence on iron and ESAs by providing the options to manage anaemia using a combination of therapies. Conflict of interest The authors declare no conflicts of interest with respect to research, authorship, and/or publication of this article. References 1. Xia H, Ebben J, Ma JZ, Collins AJ. Hematocrit levels and hos- pitalization risks in hemodialysis patients. J Am Soc Nephrol. 1999;10(6):1309–16. 2. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and asso- ciated mortality in hemodialysis patients. J Am Soc Nephrol. 1999;10(3):610–19. 3. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by bind- ing to ferroportin and inducing its internalization. Science. 2004;306(5704):2090–3. http://dx.doi.org/10.1126/science.1104742 4. Olynyk JK, Trinder D, Ramm GA, Britton RS, Bacon BR. Hereditary hemochromatosis in the post-HFE era. Hepatology. 2008;48(3):991–1001. http://dx.doi.org/10.1002/hep.22507 5. Graham RM, Chua AC, Herbison CE, Olynyk JK, Trinder D. Liver iron transport. World J Gastroenterol. 2007;13(35):4725–36. http://dx.doi.org/10.3748/wjg.v13.i35.4725 6. Chua AC, Graham RM, Trinder D, Olynyk JK. The regulation of cellular iron metabolism. Crit Rev Clin Lab Sci. 2007;44(5–6): 413–59. http://dx.doi.org/10.1080/10408360701428257 7. Beutler E, Hoffbrand AV, Cook JD. Iron deficiency and overload. Hematology Am Soc Hematol Educ Program. 2003:40–61. http:// dx.doi.org/10.1182/asheducation-2003.1.40 8. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, et al. Efficacy of deferoxamine in pre- venting complications of iron overload in patients with thalasse- mia major. N Engl J Med. 1994;331(9):567–73. http://dx.doi.org/ 10.1056/NEJM199409013310902 9. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001;276(11):7806–10. http://dx.doi.org/10.1074/jbc.M008922200 10. Ramey G, Deschemin JC, Durel B, Canonne-Hergaux F, Nicolas G, Vaulont S. Hepcidin targets ferroportin for degradation in hepatocytes. Haematologica. 2010;95(3):501–4. http://dx.doi.org/ 10.3324/haematol.2009.014399 11. Sow FB, Florence WC, Satoskar AR, Schlesinger LS, Zwilling BS, Lafuse WP. Expression and localization of hepcidin in macro- phages: A role in host defense against tuberculosis. J Leukoc Biol. 2007;82(4):934–45. http://dx.doi.org/10.1189/jlb.0407216 12. De Domenico I, Zhang TY, Koening CL, Branch RW, London N, LO E, et al. Hepcidin mediates transcriptional changes that mod- ulate acute cytokine-induced inflammatory responses in mice. J Clin Invest. 2010;120(7):2395–405. http://dx.doi.org/10.1172/ JCI42011 Krishnan AR et al. Codon Publications Journal of Renal and Hepatic Disorders 2017; 1(1): 11–19 16 http://dx.doi.org/10.1126/science.1104742 http://dx.doi.org/10.1002/hep.22507 http://dx.doi.org/10.3748/wjg.v13.i35.4725 http://dx.doi.org/10.1080/10408360701428257 http://dx.doi.org/10.1182/asheducation-2003.1.40 http://dx.doi.org/10.1182/asheducation-2003.1.40 http://dx.doi.org/10.1056/NEJM199409013310902 http://dx.doi.org/10.1056/NEJM199409013310902 http://dx.doi.org/10.1074/jbc.M008922200 http://dx.doi.org/10.3324/haematol.2009.014399 http://dx.doi.org/10.3324/haematol.2009.014399 http://dx.doi.org/10.1189/jlb.0407216 http://dx.doi.org/10.1172/JCI42011 http://dx.doi.org/10.1172/JCI42011 13. Core AB, Canali S, Babitt JL. Hemojuvelin and bone morphoge- netic protein (BMP) signaling in iron homeostasis. Front Pharmacol. 2014;5:104. http://dx.doi.org/10.3389/fphar.2014.00104 14. RamosE,KautzL,Rodriguez R,HansenM,GabayanV,Ginzburg Y, et al. Evidence for distinct pathways of hepcidin regulation by acute and chronic iron loading in mice. Hepatology. 2011;53(4): 1333–41. http://dx.doi.org/10.1002/hep.24178 15. Corradini E, Meynard D, Wu Q, Chen S, Ventura P, Pietrangelo A, et al. Serum and liver iron differently regulate the bone mor- phogenetic protein 6 (BMP6)-SMAD signaling pathway in mice. Hepatology. 2011;54(1):273–84. http://dx.doi.org/10. 1002/hep.24359 16. Bridle KR, Frazer DM, Wilkins SJ, Dixon JL, Purdie DM, Crawford DH, et al. Disrupted hepcidin regulation in HFE- associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet. 2003;361(9358):669–73. http://dx.doi. org/10.1016/S0140-6736(03)12602-5 17. Nemeth E, Roetto A, Garozzo G, Ganz T, Camaschella C. Hepcidin is decreased in TFR2 hemochromatosis. Blood. 2005; 105(4):1803–6. http://dx.doi.org/10.1182/blood-2004-08-3042 18. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002;110(7):1037–44. http://dx.doi.org/10.1172/JCI0215686 19. Nemeth E, Rivera S, Gabayan V, Keller V, Taudorf S, Pedersen BK, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113(9):1271–6. http://dx.doi.org/10.1172/JCI200420945 20. Besson-Fournier C, Latour C, Kautz L, Bertrand J, Ganz T, Roth MP, et al. Induction of activin B by inflammatory stimuli up-regulates expression of the iron-regulatory peptide hepcidin through Smad1/5/8 signaling. Blood. 2012;120(2):431–9. http:// dx.doi.org/10.1182/blood-2012-02-411470 21. Semenza GL. HIF-1: Mediator of physiological and pathophy- siological responses to hypoxia. J Appl Physiol (1985). 2000;88 (4):1474–80. 22. Greijer AE, van der Groep P, Kemming D, Shvarts A, Semenza D, Meijer GA, et al. Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). J Pathol. 2005;206(3):291–304. http://dx.doi.org/10. 1002/path.1778 23. Fan C, Iacobas DA, Zhou D, Chen Q, Lai JK, Gavrialov O, et al. Gene expression and phenotypic characterization of mouse heart after chronic constant or intermittent hypoxia. Physiol Genomics. 2005;22(3):292–307. http://dx.doi.org/10. 1152/physiolgenomics.00217.2004 24. Liu Q, Davidoff O, Niss K, Haase VH. Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. J Clin Invest. 2012;122(12):4635–44. https://dx.doi.org/10.1172/ JCI63924 25. Piperno A, Galimberti S, Mariani R, Pelucchi S, Ravasi G, Lombardi C, et al. Modulation of hepcidin production during hypoxia-induced erythropoiesis in humans in vivo: Data from the HIGHCARE project. Blood. 2011;117(10):2953–9. http:// dx.doi.org/10.1182/blood-2010-08-299859 26. Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46(7):678–84. http://dx.doi. org/10.1038/ng.2996 27. Kautz L, Nemeth E. Molecular liaisons between erythropoiesis and iron metabolism. Blood. 2014;124(4):479–82. http://dx.doi. org/10.1182/blood-2014-05-516252 28. Shoji S, Inaba M, Tomosugi N, Okuno S, Ichii M, Yamakawa T, et al. Greater potency of darbepoetin-alpha than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients. Eur J Haematol. 2013;90(3):237–44. http://dx.doi.org/10.1111/ejh.12067 29. Onuma S, Honda H, Kobayashi Y, Yamamoto T, Michihata T, Shibagaki K, et al. Effects of long-term erythropoiesis-stimulating agents on iron metabolism in patients on hemodialysis. Ther Apher Dial. 2015;19(6):582–9. http://dx.doi.org/10.1111/1744- 9987.12322 30. Honda H, Kobayashi Y, Onuma S, Shibagaki K, Yuza T, Hirao K, et al. Associations among erythroferrone and biomarkers of erythropoiesis and iron metabolism, and treatment with long-term erythropoiesis-stimulating agents in patients on hemo- dialysis. PLoS One. 2016;11(3):e0151601. http://dx.doi.org/10. 1371/journal.pone.0151601 31. McClellan WM, Flanders WD, Langston RD, Jurkovitz C, Presley R. Anemia and renal insufficiency are independent risk fac- tors for death among patients with congestive heart failure admitted to community hospitals: A population-based study. J Am Soc Nephrol. 2002;13(7):1928–36. http://dx.doi.org/10. 1097/01.ASN.0000018409.45834.FA 32. Astor BC, Arnett DK, Brown A, Coresh J. Association of kidney function and hemoglobin with left ventricular morphology among African Americans: The Atherosclerosis Risk in Commu- nities (ARIC) study. Am J Kidney Dis. 2004;43(5):836–45. http:// dx.doi.org/10.1053/j.ajkd.2003.12.047 33. Panwar B, Gutierrez OM. Disorders of iron metabolism and anemia in chronic kidney disease. Semin Nephrol. 2016;36(4): 252–61. http://dx.doi.org/10.1016/j.semnephrol.2016.05.002 34. Young B, Zaritsky J. Hepcidin for clinicians. Clin J Am Soc Nephrol. 2009;4(8):1384–7. http://dx.doi.org/10.2215/CJN. 02190309 35. Kuragano T, Shimonaka Y, Kida A, Furuta M, Nanami M, Otaki Y, et al. Determinants of hepcidin in patients on mainte- nance hemodialysis: Role of inflammation. Am J Nephrol. 2010;31(6):534–40. http://dx.doi.org/10.1159/000312381 36. Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, et al. Hepcidin – A potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(6):1051–6. http://dx.doi.org/10.2215/CJN.05931108 37. Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int. 2009;75(9): 976–81. http://dx.doi.org/10.1038/ki.2009.21 38. Weiss G, Theurl I, Eder S, Koppelstaetter C, Kurz K, Sonnweber T, et al. Serum hepcidin concentration in chronic haemodialysis patients: Associations and effects of dialysis, iron and erythropoie- tin therapy. Eur J Clin Invest. 2009;39(10):883–90. http://dx.doi. org/10.1111/j.1365-2362.2009.02182.x 39. Milward EA, Trinder D, Wilcox CE, Britton RS, Ramm GA, Olynyk JK. Is HFE involved in increased hepcidin expression and hypoferremia in inflammation and anemia of chronic dis- ease? Hepatology. 2005;41(4):936–8. http://dx.doi.org/10.1002/ hep.20652 40. Eleftheriadis T, Liakopoulos V, Antoniadi G, Kartsios C, Stefanidis I. The role of hepcidin in iron homeostasis and anemia in hemodialysis patients. Semin Dial. 2009;22(1):70–7. http://dx. doi.org/10.1111/j.1525-139X.2008.00532.x 41. Pecoits-Filho R, Lindholm B, Axelsson J, Stenvinkel P. Update on interleukin-6 and its role in chronic renal failure. Nephrol Dial Transplant. 2003;18(6):1042–5. http://dx.doi.org/10.1093/ ndt/gfg111 Anaemia of chronic kidney disease Codon Publications Journal of Renal and Hepatic Disorders 2017; 1(1): 11–19 17 http://dx.doi.org/10.3389/fphar.2014.00104 http://dx.doi.org/10.1002/hep.24178 http://dx.doi.org/10.1002/hep.24359 http://dx.doi.org/10.1002/hep.24359 http://dx.doi.org/10.1016/S0140-6736(03)12602-5 http://dx.doi.org/10.1016/S0140-6736(03)12602-5 http://dx.doi.org/10.1182/blood-2004-08-3042 http://dx.doi.org/10.1172/JCI0215686 http://dx.doi.org/10.1172/JCI200420945 http://dx.doi.org/10.1182/blood-2012-02-411470 http://dx.doi.org/10.1182/blood-2012-02-411470 http://dx.doi.org/10.1002/path.1778 http://dx.doi.org/10.1002/path.1778 http://dx.doi.org/10.1152/physiolgenomics.00217.2004 http://dx.doi.org/10.1152/physiolgenomics.00217.2004 https://dx.doi.org/10.1172/JCI63924 https://dx.doi.org/10.1172/JCI63924 http://dx.doi.org/10.1182/blood-2010-08-299859 http://dx.doi.org/10.1182/blood-2010-08-299859 http://dx.doi.org/10.1038/ng.2996 http://dx.doi.org/10.1038/ng.2996 http://dx.doi.org/10.1182/blood-2014-05-516252 http://dx.doi.org/10.1182/blood-2014-05-516252 http://dx.doi.org/10.1111/ejh.12067 http://dx.doi.org/10.1111/1744-9987.12322 http://dx.doi.org/10.1111/1744-9987.12322 http://dx.doi.org/10.1371/journal.pone.0151601 http://dx.doi.org/10.1371/journal.pone.0151601 http://dx.doi.org/10.1097/01.ASN.0000018409.45834.FA http://dx.doi.org/10.1097/01.ASN.0000018409.45834.FA http://dx.doi.org/10.1053/j.ajkd.2003.12.047 http://dx.doi.org/10.1053/j.ajkd.2003.12.047 http://dx.doi.org/10.1016/j.semnephrol.2016.05.002 http://dx.doi.org/10.2215/CJN.02190309 http://dx.doi.org/10.2215/CJN.02190309 http://dx.doi.org/10.1159/000312381 http://dx.doi.org/10.2215/CJN.05931108 http://dx.doi.org/10.1038/ki.2009.21 http://dx.doi.org/10.1111/j.1365-2362.2009.02182.x http://dx.doi.org/10.1111/j.1365-2362.2009.02182.x http://dx.doi.org/10.1002/hep.20652 http://dx.doi.org/10.1002/hep.20652 http://dx.doi.org/10.1111/j.1525-139X.2008.00532.x http://dx.doi.org/10.1111/j.1525-139X.2008.00532.x http://dx.doi.org/10.1093/ndt/gfg111 http://dx.doi.org/10.1093/ndt/gfg111 42. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immu- noassay for human serum hepcidin. Blood. 2008;112(10):4292–7. http://dx.doi.org/10.1182/blood-2008-02-139915 43. Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: Implications for the anemia of CKD. Am J Kidney Dis. 2010;55 (4):726–41. http://dx.doi.org/10.1053/j.ajkd.2009.12.030 44. Vos FE, Schollum JB, Coulter CV, Doyle TC, Duffull SB, Walker RJ. Red blood cell survival in long-term dialysis patients. Am J Kidney Dis. 2011;58(4):591–8. http://dx.doi.org/10.1053/j. ajkd.2011.03.031 45. Eschbach JW Jr., Funk D, Adamson J, Kuhn I, Scribner BH, Finch CA. Erythropoiesis in patients with renal failure under- going chronic dialysis. N Engl J Med. 1967;276(12):653–8. http://dx.doi.org/10.1056/NEJM196703232761202 46. Alon DB, Chaimovitz C, Dvilansky A, Lugassy G, Douvdevani A, Shany S, et al. Novel role of 1,25(OH)(2)D(3) in induction of erythroid progenitor cell proliferation. Exp Hematol. 2002;30(5): 403–9. http://dx.doi.org/10.1016/S0301-472X(02)00789-0 47. Bacchetta J, Zaritsky JJ, Sea JL, Chun RF, Lisse TS, Zavala K, et al. Suppression of iron-regulatory hepcidin by vitamin D. J Am Soc Nephrol. 2014;25(3):564–72. http://dx.doi.org/10.1681/ ASN.2013040355 48. SazawalS,BlackRE,RamsanM,ChwayaHM,StoltzfusRJ,Dutta A, et al. Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: Community-based, randomised, placebo-controlled trial. Lancet. 2006;367(9505): 133–43. http://dx.doi.org/10.1016/S0140-6736(06)67962-2 49. Boelaert JR, Vandecasteele SJ, Appelberg R, Gordeuk VR. The effect of the host’s iron status on tuberculosis. J Infect Dis. 2007;195(12):1745–53. http://dx.doi.org/10.1086/518040 50. McDermid JM, Jaye A, Schim van der Loeff MF, Todd J, Bates C, Austin S, et al. Elevated iron status strongly predicts mortality in West African adults with HIV infection. J Acquir Immune Defic Syndr. 2007;46(4):498–507. http://dx.doi.org/10.1097/ QAI.0b013e31815b2d4b 51. Litton E, Baker S, Erber W, French C, Ferrier J, Hawkins D, et al. The IRONMAN trial: A protocol for a multicentre rando- mised placebo-controlled trial of intravenous iron in intensive care unit patients with anaemia. Crit Care Resusc. 2014;16(4): 285–90. 52. Barany P, Eriksson LC, Hultcrantz R, Pettersson E, Bergstrom J. Serum ferritin and tissue iron in anemic dialysis patients. Miner Electrolyte Metab. 1997;23(3–6):273–6. 53. Hentze MW, Muckenthaler MU, Andrews NC. Balancing acts: Molecular control of mammalian iron metabolism. Cell. 2004;117(3):285–97. http://dx.doi.org/10.1016/S0092-8674(04) 00343-5 54. Saeed O, Otsuka F, Polavarapu R, Karmali V, Weiss D, Davis T, et al. Pharmacological suppression of hepcidin increases macrophage cholesterol efflux and reduces foam cell formation and atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32 (2):299–307. http://dx.doi.org/10.1161/ATVBAHA.111.240101 55. Wilson JG. Iron and glucose homeostasis: New lessons from her- editary haemochromatosis. Diabetologia. 2006;49(7):1459–61. http://dx.doi.org/10.1007/s00125-006-0289-1 56. Drueke T, Witko-Sarsat V, Massy Z, Descamps-Latscha Z, Guerin AP, Marchais SJ, et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation. 2002;106(17):2212–17. http://dx.doi.org/10.1161/01.CIR.0000035250.66458.67 57. van der Weerd NC, Grooteman MP, Bots ML, van den Dorpel MA, den Hoedt CH, Mazairac AH, et al. Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients. Nephrol Dial Transplant. 2013;28(12):3062–71. http://dx.doi. org/10.1093/ndt/gfs488 58. Stadler N, Lindner RA, Davies MJ. Direct detection and quanti- fication of transition metal ions in human atherosclerotic plaques: Evidence for the presence of elevated levels of iron and copper. Arterioscler Thromb Vasc Biol. 2004;24(5):949–54. http://dx.doi. org/10.1161/01.ATV.0000124892.90999.cb 59. Finn AV, Nakano M, Polavarapu R, Karmal V, Saeed O, Zhao X, et al. Hemoglobin directs macrophage differentiation and prevents foam cell formation in human atherosclerotic pla- ques. J Am Coll Cardiol. 2012;59(2):166–77. http://dx.doi.org/ 10.1016/j.jacc.2011.10.852 60. Del Vecchio L, Longhi S, Locatelli F. Safety concerns about intravenous iron therapy in patients with chronic kidney disease. Clin Kidney J. 2016;9(2):260–7. http://dx.doi.org/10.1093/ckj/ sfv142 61. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339 (9):584–90. http://dx.doi.org/10.1056/NEJM199808273390903 62. Besarab A, Goodkin DA, Nissenson AR, Normal Hematocrit Cardiac Trial Authors. The normal hematocrit study – Follow- up. N Engl J Med. 2008;358(4):433–4. http://dx.doi.org/10.1056/ NEJMc076523 63. Levin NW, Lazarus JM, Nissenson AR. National cooperative rHu erythropoietin study in patients with chronic renal failure – An interim report. The national cooperative rHu erythropoie- tin study group. Am J Kidney Dis. 1993;22(2 Suppl 1):3–12. http://dx.doi.org/10.1016/0272-6386(93)70176-Y 64. Parfrey PS, Lauve M, Latremouille-Viau D, Lefebvre P. Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: A meta-analysis. Clin J Am Soc Nephrol. 2009;4(4):755–62. http://dx.doi.org/10.2215/CJN.02730608 65. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355(20):2071–84. http://dx.doi.org/10.1056/NEJMoa062276 66. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kid- ney disease. N Engl J Med. 2006;355(20):2085–98. http://dx. doi.org/10.1056/NEJMoa065485 67. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21): 2019–32. http://dx.doi.org/10.1056/NEJMoa0907845 68. Winkelmayer WC. Against TREATing all patients alike: Lessons from an FDA advisory committee meeting. J Am Soc Nephrol. 2011;22(1):1–2. http://dx.doi.org/10.1681/ASN.2010111133 69. Liu Y, Xu Y, Thilo F, Friis UG, Jensen BL, Scholze A, et al. Ery- thropoietin increases expression and function of transient receptor potential canonical 5 channels. Hypertension. 2011;58(2):317–24. http://dx.doi.org/10.1161/HYPERTENSIONAHA.111.173690 70. Janmaat ML, Heerkens JL, de Bruin AM, Klous A, de Waard V, de Vries CJ. Erythropoietin accelerates smooth muscle cell-rich vascular lesion formation in mice through endothelial cell activa- tion involving enhanced PDGF-BB release. Blood. 2010;115(7): 1453–60. http://dx.doi.org/10.1182/blood-2009-07-230870 71. Hedley BD, Allan AL, Xenocostas A. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression. Clin Cancer Res. 2011;17(20):6373–80. http://dx.doi.org/10.1158/ 1078-0432.CCR-10-2577 Krishnan AR et al. Codon Publications Journal of Renal and Hepatic Disorders 2017; 1(1): 11–19 18 http://dx.doi.org/10.1182/blood-2008-02-139915 http://dx.doi.org/10.1053/j.ajkd.2009.12.030 http://dx.doi.org/10.1053/j.ajkd.2011.03.031 http://dx.doi.org/10.1053/j.ajkd.2011.03.031 http://dx.doi.org/10.1056/NEJM196703232761202 http://dx.doi.org/10.1016/S0301-472X(02)00789-0 http://dx.doi.org/10.1681/ASN.2013040355 http://dx.doi.org/10.1681/ASN.2013040355 http://dx.doi.org/10.1016/S0140-6736(06)67962-2 http://dx.doi.org/10.1086/518040 http://dx.doi.org/10.1097/QAI.0b013e31815b2d4b http://dx.doi.org/10.1097/QAI.0b013e31815b2d4b http://dx.doi.org/10.1016/S0092-8674(04)00343-5 http://dx.doi.org/10.1016/S0092-8674(04)00343-5 http://dx.doi.org/10.1161/ATVBAHA.111.240101 http://dx.doi.org/10.1007/s00125-006-0289-1 http://dx.doi.org/10.1161/01.CIR.0000035250.66458.67 http://dx.doi.org/10.1093/ndt/gfs488 http://dx.doi.org/10.1093/ndt/gfs488 http://dx.doi.org/10.1161/01.ATV.0000124892.90999.cb http://dx.doi.org/10.1161/01.ATV.0000124892.90999.cb http://dx.doi.org/10.1016/j.jacc.2011.10.852 http://dx.doi.org/10.1016/j.jacc.2011.10.852 http://dx.doi.org/10.1093/ckj/sfv142 http://dx.doi.org/10.1093/ckj/sfv142 http://dx.doi.org/10.1056/NEJM199808273390903 http://dx.doi.org/10.1056/NEJMc076523 http://dx.doi.org/10.1056/NEJMc076523 http://dx.doi.org/10.1016/0272-6386(93)70176-Y http://dx.doi.org/10.2215/CJN.02730608 http://dx.doi.org/10.1056/NEJMoa062276 http://dx.doi.org/10.1056/NEJMoa065485 http://dx.doi.org/10.1056/NEJMoa065485 http://dx.doi.org/10.1056/NEJMoa0907845 http://dx.doi.org/10.1681/ASN.2010111133 http://dx.doi.org/10.1161/HYPERTENSIONAHA.111.173690 http://dx.doi.org/10.1182/blood-2009-07-230870 http://dx.doi.org/10.1158/1078-0432.CCR-10-2577 http://dx.doi.org/10.1158/1078-0432.CCR-10-2577 72. Hung SC, Lin YP, Tarng DC. Erythropoiesis-stimulating agents in chronic kidney disease: What have we learned in 25 years? J Formos Med Assoc. 2014;113(1):3–10. http://dx.doi.org/10. 1016/j.jfma.2013.09.004 73. Freitas JP, Filipe PM. Pentoxifylline. A hydroxyl radical scavenger. Biol Trace Elem Res. 1995;47(1–3):307–11. http://dx.doi.org/10. 1007/BF02790131 74. Bienvenu J, Doche C, Gutowski MC, Lenoble M, Lepape A, Perdrix JP. Production of proinflammatory cytokines and cytokines involved in the TH1/TH2 balance is modulated by pentoxifylline. J Cardiovasc Pharmacol. 1995;25(Suppl 2):S80–4. http://dx.doi. org/10.1097/00005344-199500252-00017 75. Benbernou N, Esnault S, Potron G, Guenounou M. Regulatory effects of pentoxifylline on T-helper cell-derived cytokine pro- duction in human blood cells. J Cardiovasc Pharmacol. 1995;25(Suppl 2):S75–9. http://dx.doi.org/10.1097/00005344-199 500252-00016 76. Johnson DW, Pascoe EM, Badve SV, Dalziel K, Cass A, Clarke P, et al. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: The Handling Erythropoietin Resistance with Oxpentifylline (HERO) trial. Am J Kidney Dis. 2015;65(1):49–57. http://dx.doi.org/10.1053/j.ajkd.2014.06.020 77. Gummer J, Trengove R, Pascoe EM, Badve SV, Cass A, Clarke P, et al. Association between serum hepcidin-25 and primary resis- tance to erythropoiesis stimulating agents in chronic kidney disease: A secondary analysis of the HERO trial. Nephrology (Carlton). 2016. http://dx.doi.org/10.1111/nep.12815 [Epub ahead of print]. 78. Ferrari P, Mallon D, Trinder D, Olynyk JK. Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease. Nephrology (Carlton). 2010;15(3):344–9. http://dx.doi. org/10.1111/j.1440-1797.2009.01203.x 79. Bolignano D, D’Arrigo G, Pisano A, Coppolino G. Pentoxifylline for anemia in chronic kidney disease: A systematic review and meta-analysis. PLoS One. 2015;10(8):e0134104. http://dx.doi. org/10.1371/journal.pone.0134104 80. Besarab A, Chernyavskaya E, Motylev I, Shutov E, Kumbar LM, Gurevich K, et al. Roxadustat (FG-4592): Correction of anemia in incident dialysis patients. J Am Soc Nephrol. 2016;27(4):1225–33. http://dx.doi.org/10.1681/ASN.2015030241 81. Pergola PE, Spinowitz BS, Hartman CS, Maroni BJ, Haase VH. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney dis- ease. Kidney Int. 2016;90(5):1115–22. http://dx.doi.org/10.1016/ j.kint.2016.07.019 82. Flamme I, Oehme F, Ellinghaus P, Jeske M, Keldenich J, Thuss U. Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production with- out hypertensive effects. PLoS One. 2014;9(11):e111838. http:// dx.doi.org/10.1371/journal.pone.0111838 83. Holdstock L, Meadowcroft AM, Maier R, Johnson BM, Jones D, Rastogi A, et al. Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia. J Am Soc Nephrol. 2016;27(4):1234–44. http://dx. doi.org/10.1681/ASN.2014111139 84. Maxwell PH, Eckardt KU. HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond. Nat Rev Nephrol. 2016;12(3):157–68. http://dx.doi.org/10.1038/nrneph.2015.193 85. Krock BL, Skuli N, Simon MC. Hypoxia-induced angiogenesis: Good and evil. Genes Cancer. 2011;2(12):1117–33. http://dx.doi. org/10.1177/1947601911423654 86. Kapitsinou PP, Rajendran G, Astleford L, Michael M, Schonfeld MP, Fields T, et al. The endothelial prolyl-4-hydroxylase domain 2/hypoxia-inducible factor 2 axis regulates pulmonary artery pressure in mice. Mol Cell Biol. 2016;36(10):1584–94. http://dx. doi.org/10.1128/MCB.01055-15 87. Semenza GL. Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu Rev Pathol. 2014;9:47–71. http://dx.doi.org/10.1146/annurev-pathol-012513-104720 88. Cooke KS, Hinkle B, Salimi-Moosavi H, Foltz I, King C, Rathanaswami P, et al. A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates. Blood. 2013;122(17):3054–61. http://dx.doi.org/10.1182/blood- 2013-06-505792 89. Badve SV, Palmer SC, Strippoli GF, Roberts MA, Teixeira- Pinto A, Boudville N, et al. The validity of left ventricular mass as a surrogate end point for all-cause and cardiovascular mortality outcomes in people with CKD: A systematic review and meta-analysis. Am J Kidney Dis. 2016;68(4):554–63. http://dx.doi.org/10.1053/j.ajkd.2016.03.418 90. Carvalho C, Isakova T, Collerone G, Olbina G, Wolf M, Westerman M, et al. Hepcidin and disordered mineral metabolism in chronic kidney disease. Clin Nephrol. 2011;76(2):90–8. http:// dx.doi.org/10.5414/CN107018 91. Icardi A, Paoletti E, De Nicola L, Mazzaferro S, Russo R, Cozzolino M. Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: The potential role of inflammation. Nephrol Dial Transplant. 2013;28(7):1672–9. http://dx.doi.org/10.1093/ndt/gft021 92. Zughaier SM, Alvarez JA, Sloan JH, Konrad RJ, Tangpricha V. The role of vitamin D in regulating the iron-hepcidin-ferroportin axis in monocytes. J Clin Transl Endocrinol. 2014;1(1):19–25. http://dx.doi.org/10.1016/j.jcte.2014.01.003 Anaemia of chronic kidney disease Codon Publications Journal of Renal and Hepatic Disorders 2017; 1(1): 11–19 19 http://dx.doi.org/10.1016/j.jfma.2013.09.004 http://dx.doi.org/10.1016/j.jfma.2013.09.004 http://dx.doi.org/10.1007/BF02790131 http://dx.doi.org/10.1007/BF02790131 http://dx.doi.org/10.1097/00005344-199500252-00017 http://dx.doi.org/10.1097/00005344-199500252-00017 http://dx.doi.org/10.1097/00005344-199500252-00016 http://dx.doi.org/10.1097/00005344-199500252-00016 http://dx.doi.org/10.1053/j.ajkd.2014.06.020 http://dx.doi.org/10.1111/nep.12815 http://dx.doi.org/10.1111/j.1440-1797.2009.01203.x http://dx.doi.org/10.1111/j.1440-1797.2009.01203.x http://dx.doi.org/10.1371/journal.pone.0134104 http://dx.doi.org/10.1371/journal.pone.0134104 http://dx.doi.org/10.1681/ASN.2015030241 http://dx.doi.org/10.1016/j.kint.2016.07.019 http://dx.doi.org/10.1016/j.kint.2016.07.019 http://dx.doi.org/10.1371/journal.pone.0111838 http://dx.doi.org/10.1371/journal.pone.0111838 http://dx.doi.org/10.1681/ASN.2014111139 http://dx.doi.org/10.1681/ASN.2014111139 http://dx.doi.org/10.1038/nrneph.2015.193 http://dx.doi.org/10.1177/1947601911423654 http://dx.doi.org/10.1177/1947601911423654 http://dx.doi.org/10.1128/MCB.01055-15 http://dx.doi.org/10.1128/MCB.01055-15 http://dx.doi.org/10.1146/annurev-pathol-012513-104720 http://dx.doi.org/10.1182/blood-2013-06-505792 http://dx.doi.org/10.1182/blood-2013-06-505792 http://dx.doi.org/10.1053/j.ajkd.2016.03.418 http://dx.doi.org/10.5414/CN107018 http://dx.doi.org/10.5414/CN107018 http://dx.doi.org/10.1093/ndt/gft021 http://dx.doi.org/10.1016/j.jcte.2014.01.003